Ronnda Bartel has served as CTO of Avery Therapeutics, Inc. since 2022, and is responsible for product development and GMP operations. Dr. Bartel is an experienced executive with 30+ years of experience in the development and manufacturing of cell-based therapeutics. She was involved in the development and approval
of some of the first cell-based products approved by the FDA and has focused her career on CMC development and manufacturing operations for early-stage companies. She has been a featured speaker at international stem cell and cell therapy conferences and a lecturer at the University of Michigan and California Polytechnical Institute. Her previous positions include Chief Scientific Officer and Vice President of Technical Operations at Aastrom Biosciences, Vice President of Scientific Development at StemCells Inc and Senior Principal Scientist at Advanced Tissue Sciences. Dr. Bartel received her bachelor’s degree with a double major in biology and chemistry from Tabor College and a Ph.D. in biochemistry from the University of Kansas.